A Vanderbilt research team provides strong evidence that new, or atypical, antipsychotic drugs carry the same cardiovascular risk as older, or typical, antipsychotic drugs. Their findings appeared in the Jan. 15 issue of the New England Journal of Medicine. The atypical antipsychotics have one important advantage over their older counterpart: They are less likely to cause very serious movement disorders like Parkinson’s disease and tardive dyskinesia. Researchers included Wayne Ray, MS’74, PhD’81, professor of preventive medicine; Dr. C. Michael Stein, the Dan May Professor of Medicine and professor of pharmacology; and Dr. Katherine Murray, associate professor of medicine and pharmacology.